Annual Meeting and Investor Day May 25, 2017 Meeting Agenda May - PowerPoint PPT Presentation

Annual Meeting and Investor Day May 25, 2017

Meeting Agenda – May 25th 8:00 – 8:30am Annual Shareholders Meeting Analyst/Investor Day Presentations 8:30 – 9:15am CEO Review 9:15 – 10:00am Pathologist Perspective 10:00 – 10:15am Break 10:15 – 11:00am Pharma Services 11:00 – 12:00am R&D and New Test Development Noon - 1:00pm Lunch/Review of Governmental Affairs 12:10pm – 1:30pm- Lab Tours – leaving every 20 minutes 2

Annual Shareholder Meeting May 25, 2017

Investor/Analyst Day Presentations May 25, 2017

Meeting Agenda – May 25th 8:00 – 8:30am Annual Shareholders Meeting Analyst/Investor Day Presentations 8:30 – 9:15am CEO Review 9:15 – 10:00am Pathologist Perspective 10:00 – 10:15am Break 10:15 – 11:00am Pharma Services 11:00 – 12:00am R&D and New Test Development Noon - 1:00pm Lunch/Review of Governmental Affairs 12:10pm – 1:30pm- Lab Tours – leaving every 20 minutes 5

Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements. Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events. 6

CEO Summary Douglas VanOort Chairman & CEO

NeoGenomics Vision By providing uncompromising quality, exceptional service and innovative solutions, we will be the World’s leading cancer testing and information company. 8

NeoGenomics - Facts • # 1 or 2 largest somatic cancer testing Lab in America • Approximately 650,000 tests will be performed in 2017 • Approx. 160,000 SF of space, 1,000 employees, 50 Physicians and PhDs • Most advanced and comprehensive cancer testing menu in America • Outstanding franchise with Hospitals/Pathologists • Unique and Growing business with Pharma clients • Large market, fragmented industry, and very positive demographic trends 9

Drive for Growth Clinical Genetic Testing Annual Revenue Clinical Genetic Tests Performed ($, 000s ) $214,708 563,132 $188,374 490,450 $82,194 177,279 $66,467 137,317 $59,866 114,606 $43,484 76,288 57,332 $34,371 45,675 $29,469 32,539 $20,015 $11,505 20,998 $6,476 12,838 $558 $1,885 4,082 1,152 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Pro Forma Clarient 2015 Genetic Test Revenue Pro Forma Clarient 2015 Clinical Genetic Tests NEO Clinical Genetic Testing Revenue NEO Clincial Genetic Tests Performed * Base NEO represents organic revenue and test volume growth from legacy business and excludes the impacts from the PathLogic and Clarient acquisitions. 10

Impact of Clarient Acquisition Outstanding Customer Mix The Deal – Closed on 12/30/15  Approx. $292 million purchase price --- $80mm cash, 15mm New BIOPHARMA shares of NEO, $110mm Pfd. Stock. SIMILAR CLINICAL CUSTOMERS  CUSTOMERS Clarient 2015 revenue $125mm and $9mm Adj EBITDA. (200 Projects with (About 2,400) >30 Customers)  $55 mm of Pfd Stock Redeemed at 9.1% discount in Dec 16  Bank debt refinanced in Dec 16 at favorable rates (L+350)  GE currently holds 15mm NEO shares plus $45mm Pfd Stock. Similar Product Lines (1) Key Benefits Other  Synergy potential of $20mm-$30mm within 3 years Cyto 5% 5%  East Coast/West Coast Labs w/similar instrumentation Molecular  Combine Irvine Lab into 78,000 sq. ft. Aliso Viejo Lab IHC 15% 42%  Strategic leadership in Heme cancers and Solid tumors  Significant Pharma Services business. FLOW 14% FISH/ISH 19% 11 (1) Clinical operations only. Percentage of tests Performed . 11 Confidential

Post Acquisition – Focus on Client Retention Quarterly Revenue (millions) $70 Revenue flat during Integration $60 $50 $24.6 $30.7 $28.9 $29.4 Revenue up 29% over 6 $40 quarters pre-acquisition Clarient Rev Neo Rev $61.7 $30 $0.7 $20 $35.9 $32.4 $31.8 $30.3 $26.6 $25.0 $25.1 $24.4 $23.2 $23.0 $20.7 $10 $0 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 12

Integration Complete After 15 months, as of March 31, 2017, Integration is 100% complete. • Sales force completely integrated after 2 months • All “back - office” systems and processes integrated after 6 months • LIS reprogrammed to incorporate Best Practices after 8 months • Corporate culture and incentive programs fully integrated within 9-12 months • All clients serviced from common LIS and Billing system after 12 months • Irvine Lab completely consolidated into Aliso Viejo Lab after 15 months After 16 months, Client Retention is nearly 100%. 13

New NeoGenomics Same historically successful attributes : • Growth orientation • Leadership in Innovation • Entrepreneurialism • Exceptional Quality/Service • Deep/comprehensive test menu • Low-cost testing processes • Strong culture • Scale from doubling our volume • Improved Profitability 14

Pursuit of Growth - Again Growth Goals: • Mid-teens organic clinical volume growth • 20%+ organic Pharma revenue growth • 25-35% incremental Adjusted EBITDA on revenue growth Driven by: • Market share gains • Demographics and medical advances • Innovation in test development • Increased efficiencies 15

U.S. Cancer Testing Market • Based on CMS Data, the Cancer Market was $5.1B in 2014 • Assuming modest growth, the Cancer Market is about $6B in 2017 • NeoGenomics 2017 Revenue estimate of $260M --- about 5% of the market • Industry is highly fragmented – and is expected to consolidate further over time 16

Cancer Testing Industry Large Reference Labs LabCorp Quest Diagnostics About 20 M&A and Strategic Approximately $2 Billion in Recent BioReference/OPKO Consolidators Initiatives over past 12 months Oncology Testing Myriad Genetics Eurofins Pure-Play Comprehensive Oncology Labs NeoGenomics Genoptix NeoGenomics now largest and Approximately $500 million in Significant Change CSI Ocurring most profitable player Oncology Testing PhenoPath Various Regional Players Specialty Labs Exact Sciences Foundation Medicine Genomic Health Approximately $1.1 Billion in Combined Adjusted EBITDA Natera Avg growth 30%+ loss for 2017 of $450 million Oncology Testing Invitae Veracyte Fulgent Genetics Large Academic Centers, Hospitals, and Other ARUP Mayo Estimated $2.5 Billion in MD Anderson Oncology Testing Memorial Sloane Kettering Others 17

Market Demand • Aging Population – incidence increases with age • Increased Prevalence – better treatments lead to more survivors and monitoring • Scientific advances – driving targeted therapeutics • Increased cost of drugs – more careful triage Source: National Institutes of Health (NIH) 18

Demographic Tailwinds Shifting De mogr aphic s Inc ide nc e of Canc e r by Age 120.0 26.2% 100.0 24.4% 80.0 18.8% 60.0 13.8% 40.0 7.9% 5.1% 20.0 2.7% 1.0% 0.0 < 20 20- 34 35- 44 45- 54 55- 64 65- 74 74- 84 > 84 Ag e 60- 64 Ag e 65- 74 Ag e 75- 84 Ag e 85+ So urc e : Unite d Sta te s Ce nsus Bure a u So urc e : Na tio na l Ca nc e r I nstitute 19

Scientific Advances Therapeutic Example Companion or Drug Examples Area Complimentary Tests Keytruda, Opdivo, PD-L1, MSI, MMR, Tumor Immuno-Oncology and many in Mutation Burden (TMB) development Anti-EGFR, ALK EGFR, ALK, ROS1, BRAF V600E, NSCLC inhibitors, etc. MET, RET, NTRAK, etc. Ovarian and PARP Inhibitors BRCA, PTEN, ERG, MMR, Prostate HER2/neu IHC & FISH tests, Breast and Gastric Herceptin BRCA, and numerous molecular tests Vemurafenib BRAF, C-KIT, numerous FISH Melanoma (Zelboraf) tests 20